{"id":"NCT01142193","sponsor":"Upsher-Smith Laboratories","briefTitle":"Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures","officialTitle":"A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05","primaryCompletion":"2012-12","completion":"2013-01","firstPosted":"2010-06-11","resultsPosted":"2014-05-07","lastUpdate":"2014-05-22"},"enrollment":249,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"USL255","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"USL255","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to examine the safety and effectiveness of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.","primaryOutcome":{"measure":"Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline.","timeFrame":"11 weeks","effectByArm":[{"arm":"USL255","deltaMin":39.5,"sd":null},{"arm":"Placebo","deltaMin":21.65,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.001"},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":69,"countries":["United States","Argentina","Australia","Belgium","Canada","Chile","Germany","Greece","Hungary","India","Israel","New Zealand","Poland","Russia","South Africa","Spain"]},"refs":{"pmids":["25461205","24902983"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":124},"commonTop":["Somnolence","Dizziness","Fatigue","Headache","Paraesthesia"]}}